

Vyripharm Testimony before the Food and Drug Administration

Jerry Bryant, President & Managing
Member, Vyripharm Biopharmaceuticals



Need for Uniform Federal Standards

POLICY
OPTIONS
POLITIQUES

The “Wild West” marketplace of legalized cannabis in Oregon

CannabisNow

The Strange Patchwork of Edibles Regulations



The wild west of California’s cannabis delivery

University of Baltimore Law Review

Issues to Watch, Online Articles, and Series

Prophesizing Pot: LAX Marijuana Policy
Highlights the Need for Uniformity

Need for Uniform Federal Standards

- **Uniformity and normalization** – FDA regulation can allow for flexible implementation, but resolve the patchwork of standards across the country.
- **Differentiation** – Allows regulators, sellers, and consumers to properly distinguish recreational and medical products.

Vyripharm's approach: We have developed a method of analyzing the *quality* and *quantity* of components in cannabis products that can precisely measure compliance with product standards.

Information and Standards Should Be Universally Accessible

- **Accessibility** – any FDA scheme should provide regulatory guidelines and background information in a universally accessible and comprehensive manner.
- This is essential to ensure the entire supply chain has the best information and does its best to serve consumers.

Vyripharm's Approach: We have developed an interface and database that allows users to compare detailed reports on cannabis strains and products. It includes extensive information down to the strain, source, genotype, and phenotype of a particular plant.

Need for Clear Product Labeling

- **Clarity** – any regulatory scheme should also include clear guidelines for product labeling.
- This will allow consumers to differentiate products and enable better tracking to test product effectiveness.

Vyripharm's approach: We've created a method of labeling cannabis products that clearly displays key components and component levels.